Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
International Journal of Molecular Sciences · 07.05.2026 · 27 (10) · 4173
DOI: 10.3390/ijms27104173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.05.2026. Verfasst von Pin-Chi Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan. Hauptthemen laut MEDLINE: Hair Follicle, Signal Transduction, STAT Transcription Factors, Janus Kinases. Die Arbeit nennt 256 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Chang Gung Memorial Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer treatment with limited effective therapeutic options. While CIA has traditionally been attributed to direct p53-mediated cytotoxicity against rapidly proliferating keratinocytes in hair bulbs, emerging evidence suggests a more complex pathogenesis that involves immune-mediated mechanisms analogous to those in alopecia areata (AA). This review synthesizes current literature and proposes that CIA may be fundamentally driven by the collapse of hair follicle (HF) immune privilege (IP). We explore how chemotherapy-induced DNA damage and psychophysiological stress converge to trigger inflammation, characterized by interferon-γ (IFN-γ)-driven pathways, oxidative stress, and neuroimmune dysregulation. We highlight histopathological, genetic, and clinical overlaps between CIA and AA, particularly regarding the shared involvement of the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signaling pathway. Consequently, Janus kinase (JAK) inhibitors (JAKi) are evaluated as potential therapeutic agents for CIA. However, the application of JAKi in oncologic populations requires scrutiny regarding potential immunosuppression and risks of malignancies. Finally, we discuss the context-dependent roles of cytokines involved in the HF-IP collapse pathway, such as interleukin (IL)-15 and IL-1, in HF homeostasis versus inflammation, and we outline future research directions for targeted and safe therapeutic strategies that mitigate CIA without compromising cancer treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan.
- Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833401, Taiwan.
- Master of Public Health Program, College of Public Health, National Taiwan University, Taipei 100025, Taiwan.
- Department of Dermatology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan.
- Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung 807377, Taiwan.
ORCID-Profile: Pin-Chi Wang, Sebastian Yu
Förderung
- National Science and Technology Council
- Chang Gung Memorial Hospital
Zitieren
APA
Wang, P. C., & Yu, S. (2026). Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling. International Journal of Molecular Sciences, 27(10), 4173. https://doi.org/10.3390/ijms27104173
Vancouver
Wang PC, Yu S. Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling. International Journal of Molecular Sciences. 2026;27(10):4173. doi:10.3390/ijms27104173
BibTeX
@article{Wang2026,
author = {Wang, Pin-Chi and Yu, Sebastian},
title = {Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4173},
doi = {10.3390/ijms27104173}
}
EUVIMED